JP2019516665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516665A5 JP2019516665A5 JP2018546587A JP2018546587A JP2019516665A5 JP 2019516665 A5 JP2019516665 A5 JP 2019516665A5 JP 2018546587 A JP2018546587 A JP 2018546587A JP 2018546587 A JP2018546587 A JP 2018546587A JP 2019516665 A5 JP2019516665 A5 JP 2019516665A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminal
- mhc
- multimeric
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 128
- 229920001184 polypeptide Polymers 0.000 claims 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims 117
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 25
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 25
- 230000002519 immonomodulatory effect Effects 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 16
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 16
- 210000004899 c-terminal region Anatomy 0.000 claims 16
- 238000000034 method Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302654P | 2016-03-02 | 2016-03-02 | |
| US62/302,654 | 2016-03-02 | ||
| PCT/US2017/020276 WO2017151818A2 (en) | 2016-03-02 | 2017-03-01 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516665A JP2019516665A (ja) | 2019-06-20 |
| JP2019516665A5 true JP2019516665A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
Family
ID=59743228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546587A Pending JP2019516665A (ja) | 2016-03-02 | 2017-03-01 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190062400A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3423108A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019516665A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180132663A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109311945A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017226269B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014458A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261401A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017151818A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| BR112018073606A2 (pt) * | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
| WO2017201131A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| WO2018119114A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| JP2021500855A (ja) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ， インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
| JP2020534352A (ja) * | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| AU2020282736B2 (en) * | 2019-05-29 | 2025-10-30 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| AU2020348373A1 (en) * | 2019-09-20 | 2022-02-24 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| CA3155510A1 (en) | 2019-10-23 | 2021-04-29 | III Ronald D. SEIDEL | Tgf-.beta. polypeptides |
| US20230126784A1 (en) * | 2020-03-06 | 2023-04-27 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| US20240209061A1 (en) * | 2020-03-09 | 2024-06-27 | Pfizer Inc. | Fusion proteins and uses thereof |
| AU2021272895A1 (en) | 2020-05-12 | 2022-09-22 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| US20230218731A1 (en) * | 2020-05-26 | 2023-07-13 | Cue Biopharma, Inc. | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |
| WO2021242935A1 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| AU2021309842A1 (en) * | 2020-07-14 | 2023-02-16 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| AU2022262595A1 (en) * | 2021-04-21 | 2023-11-09 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| US20240270815A1 (en) * | 2021-05-26 | 2024-08-15 | Cue Biopharma, Inc. | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163602C (zh) * | 1998-04-07 | 2004-08-25 | 科里克萨公司 | 结核杆菌抗原融合蛋白及其应用 |
| PT3357511T (pt) * | 2011-06-30 | 2020-07-23 | Genzyme Corp | Inibidores da ativação de células t |
| CN102898504B (zh) * | 2012-10-23 | 2014-08-06 | 中国农业大学 | 抗氧化活性合成肽及其用途 |
| PT3480213T (pt) * | 2014-06-18 | 2020-02-04 | Albert Einstein College Medicine | Polipéptidos syntac e utilizações dos mesmos |
-
2017
- 2017-03-01 JP JP2018546587A patent/JP2019516665A/ja active Pending
- 2017-03-01 KR KR1020187028428A patent/KR20180132663A/ko not_active Ceased
- 2017-03-01 WO PCT/US2017/020276 patent/WO2017151818A2/en not_active Ceased
- 2017-03-01 CA CA3014458A patent/CA3014458A1/en not_active Abandoned
- 2017-03-01 CN CN201780027232.8A patent/CN109311945A/zh active Pending
- 2017-03-01 EP EP17760749.6A patent/EP3423108A4/en not_active Withdrawn
- 2017-03-01 AU AU2017226269A patent/AU2017226269B2/en not_active Expired - Fee Related
- 2017-03-01 US US16/077,420 patent/US20190062400A1/en not_active Abandoned
-
2018
- 2018-08-27 IL IL261401A patent/IL261401A/en unknown
-
2022
- 2022-08-12 US US17/887,199 patent/US20230227530A1/en active Pending